153 related articles for article (PubMed ID: 9815690)
21. Prevention of immunotoxin-induced immunogenicity by coadministration with CTLA4Ig enhances antitumor efficacy.
Siegall CB; Haggerty HG; Warner GL; Chace D; Mixan B; Linsley PS; Davidson T
J Immunol; 1997 Nov; 159(10):5168-73. PubMed ID: 9366448
[TBL] [Abstract][Full Text] [Related]
22. Immunological hormone atrophy by gonadotropin-based drug.
Li J; Zhang J
Int J Exp Pathol; 2006 Dec; 87(6):495-9. PubMed ID: 17222217
[TBL] [Abstract][Full Text] [Related]
23. Improved antitumor activity of a recombinant anti-Lewis(y) immunotoxin not requiring proteolytic activation.
Kuan CT; Pastan I
Proc Natl Acad Sci U S A; 1996 Feb; 93(3):974-8. PubMed ID: 8577771
[TBL] [Abstract][Full Text] [Related]
24. Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin.
Reiter Y; Kreitman RJ; Brinkmann U; Pastan I
Int J Cancer; 1994 Jul; 58(1):142-9. PubMed ID: 8014011
[TBL] [Abstract][Full Text] [Related]
25. Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: relative importance of the two toxin disulfide bonds.
Kreitman RJ; Batra JK; Seetharam S; Chaudhary VK; FitzGerald DJ; Pastan I
Bioconjug Chem; 1993; 4(2):112-20. PubMed ID: 7873642
[TBL] [Abstract][Full Text] [Related]
26. Characterization of single-chain antibody (sFv)-toxin fusion proteins produced in vitro in rabbit reticulocyte lysate.
Nicholls PJ; Johnson VG; Andrew SM; Hoogenboom HR; Raus JC; Youle RJ
J Biol Chem; 1993 Mar; 268(7):5302-8. PubMed ID: 8444903
[TBL] [Abstract][Full Text] [Related]
27. Immunotoxins made with a recombinant form of Pseudomonas exotoxin A that do not require proteolysis for activity.
Theuer CP; Kreitman RJ; FitzGerald DJ; Pastan I
Cancer Res; 1993 Jan; 53(2):340-7. PubMed ID: 8417828
[TBL] [Abstract][Full Text] [Related]
28. Cytotoxicity of recombinant Fab and Fv immunotoxins on adult T-cell leukemia lymph node and blood cells in the presence of soluble interleukin-2 receptor.
Saito T; Kreitman RJ; Hanada S; Makino T; Utsunomiya A; Sumizawa T; Arima T; Chang CN; Hudson D; Pastan I
Cancer Res; 1994 Feb; 54(4):1059-64. PubMed ID: 8313362
[TBL] [Abstract][Full Text] [Related]
29. Basic fibroblast growth factor-Pseudomonas exotoxin chimeric proteins; comparison with acidic fibroblast growth factor-Pseudomonas exotoxin.
Gawlak SL; Pastan I; Siegall CB
Bioconjug Chem; 1993; 4(6):483-9. PubMed ID: 7508267
[TBL] [Abstract][Full Text] [Related]
30. A single-chain immunotoxin against carcinoembryonic antigen that suppresses growth of colorectal carcinoma cells.
Akamatsu Y; Murphy JC; Nolan KF; Thomas P; Kreitman RJ; Leung SO; Junghans RP
Clin Cancer Res; 1998 Nov; 4(11):2825-32. PubMed ID: 9829749
[TBL] [Abstract][Full Text] [Related]
31. Monovalent immunotoxin containing truncated form of Pseudomonas exotoxin as potent antitumor agent.
Debinski W; Pastan I
Cancer Res; 1992 Oct; 52(19):5379-85. PubMed ID: 1394141
[TBL] [Abstract][Full Text] [Related]
32. Chimeric cytotoxin IL2-PE40 delays and mitigates adjuvant-induced arthritis in rats.
Case JP; Lorberboum-Galski H; Lafyatis R; FitzGerald D; Wilder RL; Pastan I
Proc Natl Acad Sci U S A; 1989 Jan; 86(1):287-91. PubMed ID: 2492102
[TBL] [Abstract][Full Text] [Related]
33. Systematic comparison of single-chain Fv antibody-fusion toxin constructs containing Pseudomonas Exotoxin A or saporin produced in different microbial expression systems.
Della Cristina P; Castagna M; Lombardi A; Barison E; Tagliabue G; Ceriotti A; Koutris I; Di Leandro L; Giansanti F; Vago R; Ippoliti R; Flavell SU; Flavell DJ; Colombatti M; Fabbrini MS
Microb Cell Fact; 2015 Feb; 14():19. PubMed ID: 25889802
[TBL] [Abstract][Full Text] [Related]
34. Expression cloning of cDNAs that render cancer cells resistant to Pseudomonas and diphtheria toxin and immunotoxins.
Brinkmann U; Brinkmann E; Pastan I
Mol Med; 1995 Jan; 1(2):206-16. PubMed ID: 8529099
[TBL] [Abstract][Full Text] [Related]
35. TGF alpha-anti-Tac(Fv)-PE40: a bifunctional toxin cytotoxic for cells with EGF or IL2 receptors.
Batra JK; Chaudhary VK; FitzGerald D; Pastan I
Biochem Biophys Res Commun; 1990 Aug; 171(1):1-6. PubMed ID: 2393383
[TBL] [Abstract][Full Text] [Related]
36. Clinical evaluation of BR96 sFv-PE40 immunotoxin therapy in canine models of spontaneously occurring invasive carcinoma.
Henry CJ; Buss MS; Hellström I; Hellström KE; Brewer WG; Bryan JN; Siegall CB
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):751-5. PubMed ID: 15701865
[TBL] [Abstract][Full Text] [Related]
37. Antitumor effects of B3-PE and B3-LysPE40 in a nude mouse model of human breast cancer and the evaluation of B3-PE toxicity in monkeys.
Pai LH; Batra JK; FitzGerald DJ; Willingham MC; Pastan I
Cancer Res; 1992 Jun; 52(11):3189-93. PubMed ID: 1591729
[TBL] [Abstract][Full Text] [Related]
38. Activity of CD4-Pseudomonas exotoxin against cells expressing diverse forms of the HIV and SIV envelope glycoproteins.
Ashorn P; Moss B; Berger EA
J Acquir Immune Defic Syndr (1988); 1992; 5(1):70-7. PubMed ID: 1738090
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms of Resistance to Immunotoxins Containing
Dieffenbach M; Pastan I
Biomolecules; 2020 Jun; 10(7):. PubMed ID: 32630017
[TBL] [Abstract][Full Text] [Related]
40. Influence of relative binding affinity on efficacy in a panel of anti-CD3 scFv immunotoxins.
Hexham JM; Dudas D; Hugo R; Thompson J; King V; Dowling C; Neville DM; Digan ME; Lake P
Mol Immunol; 2001 Sep; 38(5):397-408. PubMed ID: 11684296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
